What question did this study set out to answer?

Review the therapeutic efficacy and severe toxic side effects associated with interleukin-2 and lymphokine-activated killer cell regimens.

October 1, 2008Pathology and Immunopathology Research

Toxicity of Immunotherapy with Interleukin-2 and Lymphokine-Activated Killer Cells

View Full Paper

Ask AI

Bookmark

Authors

JMJames W. MierHadassah Medical Center FAFrederick R. AronsonNew England Cancer Specialists RNRobert P. NumerofRigel (United States)

Discussion

Member takes

Implication

Clinical review highlights severe toxicity profiles in renal cancer and melanoma patients, suggesting mechanistic insights could improve treatment safety.

Key Points

Review the therapeutic efficacy and severe toxic side effects associated with interleukin-2 and lymphokine-activated killer cell regimens.
Assessed clinical outcomes and toxicity patterns in patients receiving interleukin-2 regimens for renal cell carcinoma and malignant melanoma.
Demonstrated that interleukin-2 immunotherapy induces notable tumor regression in renal cell carcinoma and malignant melanoma.
Characterized treatment-limiting toxicities, including vascular leak syndrome, which present severe barriers to safe clinical administration.

Cite This Study

Mier et al. (2008) studied this question.

synapsesocial.com/papers/6a7f26fad45b2d58ae84e95c https://doi.org/10.1159/000157075

View Full Paper

Ask AI

Bookmark

Implication

Clinical review highlights severe toxicity profiles in renal cancer and melanoma patients, suggesting mechanistic insights could improve treatment safety.

Toxicity of Immunotherapy with Interleukin-2 and Lymphokine-Activated Killer Cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Toxicity of Immunotherapy with Interleukin-2 and Lymphokine-Activated Killer Cells

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider